EFFICACY RESULTS OF 0.2.G/DAY FLUOCINOLONE ACETONIDE IMPLANT (FAC) IN DMO VITRECTOMISED PATIENTS

被引：0
|
作者：
Erginay, A. [1 ]
Habib, M. [2 ]
Goldsmith, C. [3 ]
Schmit-Eilenberger, V. [4 ]
Massin, P. [1 ,5 ]
机构：
[1] Lariboisiere Univ Hosp, AP HP, Paris, France
[2] Sunderland Eye Hosp, Sunderland, Tyne & Wear, England
[3] James Paget Univ Hosp, Great Yarmouth, Norfolk, England
[4] Karlsruhe Eye Clin, Karlsruhe, Germany
[5] Opthalm Clin Breteuil, Paris, France
来源：
EUROPEAN JOURNAL OF OPHTHALMOLOGY | 2016年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E109 / E110
页数：2
相关论文
共 50 条
  • [21] Progression of diabetic retinopathy in patients treated with 0.2 μg/day fluocinolone acetonide (FAc) implants for diabetic macular edema (DME): a fellow eye controlled analysis
    Iezzi, Raymond
    Kapik, Barry
    Green, Ken E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [22] A retrospective evaluation of the efficacy and safety of fluocinolone acetonide 0.2 μg implant in patients with chronic diabetic macular edema with insufficient response to other therapies
    Meireles, Angelina
    Coelho, Joao
    Pessoa, Bernardete
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [23] Two-year interim safety results of the 0.2 μg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
    Mansour, Sam E.
    Kiernan, Daniel F.
    Roth, Daniel B.
    Eichenbaum, David
    Holekamp, Nancy M.
    Kaba, Samer
    Werts, Erica
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2021, 105 (03) : 414 - 419
  • [24] Clinical impact of the 0.2 μg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(R) clinical evidence study in Portugal
    Carneiro, Angela
    Meireles, Angelina
    Castro Sousa, Joao Paulo
    Teixeira, Carla
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2020, 12
  • [25] Prior steroid response as a predictor of real-world IOP safety with 0.2 μg/day fluocinolone acetonide (FAc) in diabetic macular edema (DME) therapy
    Lai, James C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [26] Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
    James F. Young
    Andrew Walkden
    Amy Stone
    Sajjad Mahmood
    Ophthalmology and Therapy, 2019, 8 : 477 - 484
  • [27] Efficacy of the 0.19 mg Fluocinolone Acetonide (FAc) Implant (ILUVIEN®) in a Multiphysician, Single-practice Setting - The Cleveland Experience
    Daroszewski, Daniel C.
    Coney, Joseph M.
    Schartman, Jerome P.
    Miller, David G.
    Rao, Llewelyn J.
    Zegarra, Hernando
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [28] Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
    Mushtaq, Bushra
    Bhatnagar, Ajay
    Palmer, Helen
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 2935 - 2943
  • [29] Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
    McCluskey, Jessica D.
    Kaufman, Paul L.
    Wynne, Kathy
    Lewis, Gregory
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2019, 12 : 93 - 102
  • [30] Reduction in treatment burden and edema in patients with diabetic macula edema following 0.2mg/day fluocinolone acetonide implant.
    Ellingson, Clinton
    Kitchens, John William
    Stone, Thomas W.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
12345